Full Year 2024 Mayne Pharma Group Ltd Earnings Call Transcript
Key Points
- Mayne Pharma Group Ltd (ASX:MYX) achieved 100% of their key operating metrics for FY24.
- Revenues increased by 112% to $388 million, driven by strong growth in women's health and dermatology segments.
- Gross margin expanded to 56.3%, representing a 24% improvement.
- Underlying EBITDA improved significantly to $22.9 million from a negative $95.3 million in FY23.
- Positive underlying operating cash flow from continuing operations of $8.1 million, an improvement of $59.6 million from FY23.
- The company faced a negative impact of $11 million due to legacy ANNOVERA short product returns.
- Second half fiscal year '24 revenue for women's health was slightly lower due to seasonality and product returns.
- Operating expenditure growth was moderated but still saw a 4% increase due to inflation and variable costs.
- Cash and marketable securities decreased to $149.3 million from $220.1 million in fiscal '23.
- The company is involved in ongoing litigation, which could result in significant legal costs.
' -
Thank you, operator, and thank you all for joining. My name is Shawn Patrick O'Brien and I am the CEO and Managing Director of Mayne Pharma. We are here to present our financial results for the 12 months ended June 30, 2024, namely FY24. Joining me on this call this morning is Mayne Pharma's CFO, Aaron Grey.
On slide 2 is an important disclaimer. Today's presentation contains forward looking statements and non-IFRS financial measures, which I draw your attention to. All dollar amounts presented today are in AUD unless otherwise noted.
Now turning to our operating metrics on slide 3. I'm delighted to announce today that in FY24, Mayne Pharma has achieved 100% of our key operating metrics or goals we set for ourselves during the financial year and we're previously communicated to the market at the start of FY24.
There were five key pillars underpinning this performance, namely deliver positive direct contribution in all three segments, return the company to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
